Overview
The Center for Biosimilars covered panel discussions from Steptoe partners Vishal Gupta and John Molenda during the American Conference Institute’s Summit on Biosimilars. During the conference, held June 25-27 in New York, Gupta discussed various naming and labeling considerations that stakeholders need to consider for biosimilars. Molenda, co-chair of Steptoe’s Healthcare & Life Sciences practice, discussed current “hot button” litigation issues in the biosimilar sphere.
Read the full articles at Center for Biosimilars (1) and Center for Biosimilars (2)
